Incyte Corporation $INCY Stake Lessened by Todd Asset Management LLC

Todd Asset Management LLC trimmed its stake in shares of Incyte Corporation (NASDAQ:INCY) by 16.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 345,023 shares of the biopharmaceutical company’s stock after selling 69,454 shares during the quarter. Todd Asset Management LLC’s holdings in Incyte were worth $29,261,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Harbor Capital Advisors Inc. bought a new position in shares of Incyte during the third quarter worth about $26,000. FNY Investment Advisers LLC bought a new position in Incyte during the 2nd quarter worth approximately $27,000. Root Financial Partners LLC acquired a new position in shares of Incyte in the 3rd quarter worth approximately $28,000. Quent Capital LLC bought a new stake in shares of Incyte in the 3rd quarter valued at approximately $30,000. Finally, MUFG Securities EMEA plc acquired a new stake in shares of Incyte during the 2nd quarter valued at approximately $32,000. Institutional investors own 96.97% of the company’s stock.

Incyte News Summary

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Q4 results & guidance: Incyte reported Q4 revenue above expectations and outlined 10–13% revenue growth for 2026, citing pipeline expansion and new product launches — a clear near-term growth signal that investors rewarded. Incyte outlines 10–13% revenue growth for 2026
• Positive Sentiment: Analyst tone: Coverage pieces and aggregate analyst commentary remain constructive—Wall Street highlights steady growth and the pipeline, helping underpin sentiment despite the EPS miss. Do Wall Street Analysts Like Incyte Corporation Stock?
• Positive Sentiment: Asset monetization: Incyte sold the Wilmington Bracebridge towers to BPG, a real-estate disposition that should free cash / simplify the corporate footprint — modestly positive for cash flow and capital allocation. Incyte’s big downtown Wilmington move…
• Neutral Sentiment: Market commentary: Several pieces ask whether INCY’s ~43% one‑year run makes it “too late” to buy; these are opinion/valuation discussions that influence positioning but don’t change fundamentals immediately. Is It Too Late To Consider Incyte After Its 43% One Year Rally
• Neutral Sentiment: Media flow: Earnings-call highlights and coverage (transcripts, midday movers) are being digested; they offer color but largely reiterate the same beats/risks. Incyte Q4 Earnings Call Highlights
• Neutral Sentiment: Short-interest data appears inconsistent/erroneous in recent filings (reports show zero shares / NaN changes), so short-interest signals aren’t informative right now.
• Negative Sentiment: Opzelura guidance & Jakafi patent fears: A weaker 2026 revenue forecast for Opzelura raised renewed concerns about franchise vulnerability and potential spillover to Jakafi patent litigation/renewed competitive risk. Opzelura weak 2026 forecast heightens Jakafi patent concerns
• Negative Sentiment: EPS miss & share reaction: INCY missed on EPS for the quarter, which prompted a post‑earnings gap down in some sessions and is a key reason for caution despite the revenue beat. Shares Gap Down After Earnings Miss
• Negative Sentiment: Regulatory/pricing risk: Management flagged exposure to evolving U.S. drug‑pricing policies (e.g., Most Favored Nation‑style measures), which could pressure profitability if enacted. Profit Outlook Threatened by Pricing Policies

Incyte Stock Performance

Shares of NASDAQ INCY opened at $101.10 on Monday. Incyte Corporation has a 12-month low of $53.56 and a 12-month high of $112.29. The company has a market cap of $20.12 billion, a PE ratio of 15.77, a P/E/G ratio of 0.80 and a beta of 0.82. The stock has a 50 day simple moving average of $101.73 and a 200-day simple moving average of $94.31. The company has a current ratio of 3.32, a quick ratio of 3.25 and a debt-to-equity ratio of 0.01.

Incyte (NASDAQ:INCY) last announced its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, missing the consensus estimate of $1.96 by ($0.16). Incyte had a net margin of 25.03% and a return on equity of 26.34%. The business had revenue of $1.51 billion for the quarter, compared to the consensus estimate of $1.35 billion. During the same period in the previous year, the firm earned $1.43 EPS. The firm’s revenue was up 27.8% on a year-over-year basis. On average, equities research analysts forecast that Incyte Corporation will post 4.86 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on INCY. Guggenheim upgraded shares of Incyte from a “neutral” rating to a “buy” rating and set a $125.00 target price for the company in a research note on Monday, November 3rd. Weiss Ratings reissued a “hold (c+)” rating on shares of Incyte in a report on Thursday, January 22nd. Barclays lifted their target price on Incyte from $115.00 to $116.00 and gave the company an “overweight” rating in a research note on Wednesday, February 4th. Truist Financial set a $103.00 price target on Incyte in a report on Wednesday, December 24th. Finally, TD Cowen restated a “buy” rating on shares of Incyte in a research note on Tuesday, January 13th. Nine equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Incyte has a consensus rating of “Hold” and an average price target of $103.94.

Insider Activity at Incyte

In related news, EVP Mohamed Khairie Issa sold 10,856 shares of the stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $109.07, for a total value of $1,184,063.92. Following the completion of the transaction, the executive vice president owned 66,132 shares in the company, valued at $7,213,017.24. This represents a 14.10% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Michael James Morrissey sold 4,323 shares of the firm’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $97.26, for a total transaction of $420,454.98. Following the transaction, the executive vice president directly owned 27,507 shares in the company, valued at approximately $2,675,330.82. The trade was a 13.58% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 95,225 shares of company stock valued at $9,519,745 in the last ninety days. Company insiders own 17.80% of the company’s stock.

About Incyte

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.